No open positions

by admin | Jan 20, 2023 | Positions

There are currently no open...

BiOrion has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients

by admin | Feb 21, 2022 | News

BiOrion Technologies BV has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients. BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for...

A consortium including BiOrion is awarded a EUROSTARS grant of a EUR 1.7 million for diagnostic imaging of colorectal cancer

by admin | Dec 11, 2020 | News

First patient enrolled in a PET-imaging study with BiOrion’s 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035 in patients with organ fibrosis.

by admin | Sep 30, 2020 | News

BiOrion Technologies announced today that a first fibrosis patient has been enrolled in the first-in-human PET imaging study with 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035. Herman Steen, CEO of BiOrion, “The enrollment of the first patient...

BiOrion concluded investment by a consortium of investors including Pharma Connect Capital

by admin | Mar 4, 2019 | News

BiOrion has raised funding from a consortium of two existing and one new investor for its further clinical validation programs in fibrosis and fibrotic cancers.  BiOrion, a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of...